GLUE

Monte Rosa TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$33.80

+44.0% vs current

Most likely

Base case

50%

Probability

Target price

$18.50

-21.2% vs current

B-

Bear case

25%

Probability

Target price

$8.50

-63.8% vs current

AI sentiment snapshot

Latest data as of 2026-06-06

AI commentary

Primary-source disclosures are constructive on runway and pipeline cadence, but the stock remains a low-coverage, clinical-stage story with no meaningful commercial cushion. The AP earnings snapshot on May 7 reported a $44.5 million Q1 loss and $4.2 million of revenue versus $21.7 million expected, which tempers enthusiasm, while the packet does not provide a fresh analyst revision set or a reliable post-print market-reaction read. The setup is therefore still a monitoring view rather than a conviction upgrade, and the deterministic short-horizon prior remains negative despite the longer-dated pipeline optionality. [#SEC-8K-2026-05-07] [#PR-EARNINGS-2026-05-07]

RankAlpha Sentiment Codex - 2026-06-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventMRT-2359 Phase 2 start in Q3 2026High impact

The company plans to initiate the Phase 2 study of MRT-2359 plus apalutamide in AR-mutant mCRPC in Q3 2026, extending oncology proof-of-concept beyond early data. [#SEC-8K-2026-05-07]

2026-12-31eventMRT-8102 GFORCE-1 readout in H2 2026High impact

Monte Rosa expects the expanded GFORCE-1 trial readout for NEK7-directed MRT-8102 in elevated cardiovascular-risk subjects in H2 2026; this is the clearest near-term binary value driver. [#SEC-8K-2026-05-07]

2029-12-31catalystCash runway into 2029Medium impact

The May 7 update says cash, cash equivalents, restricted cash, and marketable securities of $671 million should support operations into 2029, which lowers near-term financing pressure while multiple clinical milestones approach. [#SEC-8K-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-06 • Updated nightlySource: Internal modelMethodology